Browsing by Subject "Hydroxychloroquine"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Hydroxychloroquine Does not Affect CTLA-4 Expression in LRBA Deficiency: Case Report from Siblings with LRBA Deficiency
    (2020) Bukhari, Ameera; Ortega-Treviño, María F.; Padem, Nurcicek; Khojah, Amer M.; Pediatrics, School of Medicine
  • Thumbnail Image
    Item
    Hydroxychloroquine safety: A meta-analysis of randomized controlled trials
    (Elsevier, 2020-07-06) Eljaaly, Khalid; Alireza, Kasim Huseein; Alshehri, Samah; Al-Tawfiq, Jaffar A.; Medicine, School of Medicine
    Background: Hydroxychloroquine (HCQ) is currently being examined for COVID-19. No previous meta-analysis has evaluated its side effects versus placebo. We conducted this meta-analysis to compare the safety of HCQ versus placebo. Methods: Two authors independently searched PubMed and EMBASE databases for randomized controlled trials (RCTs) of adults comparing the adverse events (AEs) of HCQ versus placebo for any indication. Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs) were calculated based on random-effects models. The heterogeneity (I2) was assessed using Cochran's Q test. Results: Nine RCTs (eight were double-blind) with a total of 916 patients were included. HCQ caused significantly more skin pigmentation than placebo (Peto OR, 4.64; 95% CI, 1.13 to 19.00; P-value = 0.033; I2 = 0%). The increase in other AEs did not reach statistical significance: rash (Peto OR, 1.11; 95% CI, 0.3 to 3.77; P-value = 0.03; I2 = 0%); gastrointestinal AEs (Peto OR, 1.43; 95% CI, 0.55 to 3.72; P-value = 0.46; I2 = 15.17%); headache (Peto OR, 1.94; 95% CI, 0.65 to 5.78; P-value = 0.23; I2 = 9.99%); dizziness (Peto OR, 1.32; 95% CI, 0.49 to 3.52; P-value = 0.58; I2 = 0%); fatigue (Peto OR, 2.13; 95% CI, 0.76 to 5.98; P-value = 0.15; I2 = 0%); and visual AEs (Peto OR, 1.61; 95% CI, 0.76 to 3.41; P-value = 0.22; I2 = 0%). Cardiac toxicity was not reported. Conclusions: This meta-analysis of RCTs found a significantly higher risk of skin pigmentation in HCQ users versus placebo. More data are needed to evaluate HCQ in the context of COVID-19 treatment.
  • Thumbnail Image
    Item
    Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
    (Elsevier, 2025) Nagaraju, Ganji Purnachandra; Saddala, Madhu Sudhana; Foote, Jeremy B.; Khaliq, Ateeq M.; Masood, Ashiq; Golivi, Yuvasri; Bandi, Dhana Sekhar Reddy; Sarvesh, Sujith; Reddy, Sudhir Putty; Switchenko, Jeffrey; Carstens, Julienne L.; Akce, Mehmet; Herting, Cameron; Alese, Olatunji B.; Yoon, Karina J.; Manne, Upender; Bhasin, Manoj K.; Lesinski, Gregory B.; Sukhatme, Vikas P.; El-Rayes, Bassel F.; Medicine, School of Medicine
    Pancreatic ductal adenocarcinoma (PDAC) has a minimal (<15%) 5-year existence, in part due to resistance to chemoradiotherapy. Previous research reveals the impact of paricalcitol (P) and hydroxychloroquine (H) on altering the lysosomal fusion, decreasing stromal burden, and triggering PDAC to chemotherapies. This investigation aims to elucidate the molecular properties of the H and P combination and their potential in sensitizing PDAC to gemcitabine (G). PH potentiates the effects of G in in vitro, orthotopic mouse models, and a patient-derived xenograft model of PDAC. Proteomic and single-cell RNA sequencing (RNA-seq) analyses reveal that GPH treatment upregulates autophagy and endoplasmic reticulum (ER) stress-related transcripts. GPH treatment decreases the number of Ki67, fibroblast-associated protein (FAP), and alpha-smooth muscle actin (SMA)-expressing fibroblasts with a decrease in autophagy-related transcripts. The GPH treatment increases M1 polarization and CD4+ and CD8+ T cells and reduces CD4+ and CD8+ regulatory T cells (Tregs). These effects of GPH were confirmed in paired biopsies obtained from patients treated in a clinical trial.
  • Thumbnail Image
    Item
    A Telehealth-Based Randomized Controlled Trial: A Model for Outpatients Trials of Off-Label Medications During the COVID-19 Pandemic
    (Sage, 2021-08) Keyhani, Salomeh; Kelly, J. Daniel; Bent, Stephen; Boscardin, W. John; Shlipak, Michael G.; Leonard, Sam; Abraham, Ann; Lum, Emily; Lau, Nicholas; Austin, Charles; Oldenburg, Catherine E.; Zillich, Allan; Lopez, Lenny; Zhang, Ying; Lietman, Tom; Bravata, Dawn M.; Medicine, School of Medicine
    The study was registered at clinicaltrials.gov: NCT04363203